ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2385

Validation of Diary Score for the Assessment of Disease Activity in Candle (Chronic atypical neutrophilic dermatosis with lipodystrophy and elevated temperature) and SAVI (STING associated vasculopathy with onset in Infancy) Patients

Megha Sawhney1, Gina A. Montealegre Sanchez2, Robert Wesley3, Kost Bahar1 and Raphaela Goldbach-Mansky4, 1NIAMS, National Institutes of Health, Bethesda, MD, 2National Institute of Allergy and Infectious Diseases (NIAID), NIH, Bethesda, MD, 3Clinical Center, National Institutes of Health, Bethesda, MD, 4Translational Autoinflammatory Disease Studies, National Institute of Allergy and Infectious Diseases (NIAID), NIH, Bethesda, MD

Meeting: 2016 ACR/ARHP Annual Meeting

Date of first publication: September 28, 2016

Keywords: Clinical Response

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, November 15, 2016

Title: Pediatric Rheumatology – Clinical and Therapeutic Aspects - Poster III: Systemic JIA, Autoinflammatory Syndromes, Scleroderma, Vasculitis, Miscellaneous

Session Type: ACR Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose: CANDLE and SAVI are two rare autoinflammatory interferonopathies without validated outcome measures to assess disease activity; however, daily diaries of prominent disease symptoms have become standard in assessing clinical disease load and reporting treatment related outcomes in patients with the autoinflammatory disease spectrum CAPS (Cryopyrin associated periodic syndrome) where diary scores were accepted by the FDA in the context of drug approval. For novel AIDs with distinct organ manifestations new disease specific diaries need to be generated and validated. In pediatrics inflammatory diseases the Childhood Health Assessment Questionnaire (CHAQ), which measures physical function and the patient and physician-derived outcome measures, patient global VAS (PATG) and physician global VAS (PHYG) respectively are used to assess disease severity and response to treatment and have been used to validate patient related outcomes in the past.

Methods: The daily diary developed for NOMID was modified to reflect disease symptoms of CANDLE and SAVI. For CANDLE these include: fever, rash, joint pain, headache and fatigue (possible range, 0 to 20) For SAVI these also include respiratory symptoms and ulcerative lesions. Each symptom is rated on a scale from 0 to 4 for increasing severity. We correlated the diary score in CANDLE and SAVI patients against 6 validated outcome measures: Childhood Health Assessment Questionnaire (CHAQ), which measures physical function; physical global VAS ( PHYG); global pain assessment ( PAINGL); parent global( PARG); the patent quality of life ( PATQL) and parent QL ( PARQL) by correlating each symptom and the summary score with PHYG, PAINGL, PARG, PATQL and PARQL respectively. We used Pearson correlation and 1-sample t- test to assess whether these values plausibly centered at 0. P – values were not corrected for multiple comparisons but p-values of <0.01 were considered significant.

Results: 11 CANDLE and 4 SAVI patients and 3 undifferentiated interfernopathy patients were included. Mean diary scores computed for all patients correlated well with CHAQ ( r-0.36, p<0.001).Mean diary score computed during the evaluation for CANDLE patients correlated well with CHAQ( r-0.36, p<0.001), pain global ( r- 0.48, p<0.001). Individual symptoms like fever, rash etc correlated well with these outcome measures in both CANDLE and SAVI. However, the SAVI specific parameters, respiratory symptoms and ulcerative lesions did not show any significant correlation.

Conclusion: Our study shows that diary scores exhibit validity across other outcome measures validated for unrelated pediatric inflammatory diseases, but outcome measures in SAVI need to be further refined.


Disclosure: M. Sawhney, None; G. A. Montealegre Sanchez, None; R. Wesley, None; K. Bahar, None; R. Goldbach-Mansky, Baricitinib, 9.

To cite this abstract in AMA style:

Sawhney M, Montealegre Sanchez GA, Wesley R, Bahar K, Goldbach-Mansky R. Validation of Diary Score for the Assessment of Disease Activity in Candle (Chronic atypical neutrophilic dermatosis with lipodystrophy and elevated temperature) and SAVI (STING associated vasculopathy with onset in Infancy) Patients [abstract]. Arthritis Rheumatol. 2016; 68 (suppl 10). https://acrabstracts.org/abstract/validation-of-diary-score-for-the-assessment-of-disease-activity-in-candle-chronic-atypical-neutrophilic-dermatosis-with-lipodystrophy-and-elevated-temperature-and-savi-sting-associated-vascul/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2016 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/validation-of-diary-score-for-the-assessment-of-disease-activity-in-candle-chronic-atypical-neutrophilic-dermatosis-with-lipodystrophy-and-elevated-temperature-and-savi-sting-associated-vascul/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology